Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 13/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920063 | 0.94 | ADORA1 (0.57) | ADORA1MEN1RAB9AKMT2APRKCZ | |
| SCHEMBL4403983 | 0.89 | ADORA1 (0.58) | ADORA1L3MBTL1MEN1RAB9AKMT2A | |
| SCHEMBL1919925 | 0.88 | ADORA1 (0.57) | ADORA1MEN1RAB9AKMT2APRKCZ | |
| SCHEMBL1920576 | 0.86 | ADORA1 (0.56) | ADORA1LMNAL3MBTL1MEN1RAB9A | |
| SCHEMBL1920529 | 0.85 | ADORA1 (0.59) | ADORA1 | |
| SCHEMBL1920388 | 0.80 | ADORA1 (0.61) | ADORA1LMNAMEN1RAB9AKMT2A | |
| SCHEMBL1919406 | 0.80 | ADORA1 (0.58) | ADORA1MEN1RAB9AKMT2APRKCZ | |
| SCHEMBL20280311 | 0.79 | ADORA1 (0.66) | ADORA1LMNAMEN1RAB9AKMT2A | |
| SCHEMBL1919823 | 0.78 | ADORA1 (0.56) | ADORA1MEN1RAB9AKMT2APRKCZ | |
| SCHEMBL1497952 | 0.74 | ADORA1 (1.00) | ADORA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108636-A1 | Allosteric Enhancers of th A1 Adenosine Receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2012-05-03 | — | — | US | claimed |
| EP-2326175-A2 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | King Pharmaceuticals Research and Development Inc. (US) | 2011-06-01 | — | — | EP | claimed |
| US-20090281145-A1 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2009-11-12 | — | — | US | claimed |
| WO-2009137782-A2 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20120108636-A1 | Allosteric Enhancers of th A1 Adenosine Receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2012-05-03 | — | — | US | disclosed |
| US-20120108636-A1 | Allosteric Enhancers of th A1 Adenosine Receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2012-05-03 | — | — | US | disclosed |
| US-20120108636-A1 | Allosteric Enhancers of th A1 Adenosine Receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2012-05-03 | — | — | US | disclosed |
| EP-2326175-A2 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | King Pharmaceuticals Research and Development Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20090281145-A1 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281145-A1 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281145-A1 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2009-11-12 | — | — | US | disclosed |
| WO-2009137782-A2 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137782-A2 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108636-A1 | Allosteric Enhancers of th A1 Adenosine Receptor | ADORA1, ADORA2A, TBXA2R | ADORA1 1/4885LMNA 3043/4885L3MBTL1 1384/4885 |
| US-20090281145-A1 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885LMNA 2686/4885L3MBTL1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.